Jozef Michalka

Jozef Michalka

Auto-generated profile, based on publicly available information

Jozef Michalka

Department of Internal Medicine, Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Acta Haematologica
Verified
Journal Article
Open access
HMHeidi Mocikova
Heidi Mocikova
RPRobert Pytlik
Robert Pytlik
PSPavla Stepankova
Pavla Stepankova
JMJozef Michalka
Jozef Michalka
JMJana Markova
Jana Markova
ZKZdenek Kral
Zdenek Kral
Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.

13 January 2025 in United European Gastroenterology Journal
Verified
Journal Article
Open access
LKLumir Kunovsky
Lumir Kunovsky
ETEliska Tvrdikova
Eliska Tvrdikova
JMJozef Michalka
Jozef Michalka
JTJan Trna
Jan Trna

31 July 2020 in eJHaem
Verified
Journal Article
Open access
PDF file
VPVít Procházka
Vít Procházka
DBDavid Belada
David Belada
AJAndrea Janikova
Andrea Janikova
KBKateřina Benešová
Kateřina Benešová
HMHeidi Mociková
Heidi Mociková
MTMarek Trněnỳ
Marek Trněnỳ
Twenty percent of patients with high‐tumor‐burden (HTB) follicular lymphoma (FL) develop progression/relapse of disease (POD) within 24 months of frontline immunochemotherapy. Unfortunately, about 50% of these patients die within 5 years since POD event. Rituximab maintenance was proven to reduce relapse rate in responding FL, but its role on preventing POD was not defined. We analyzed 1360 HTB‐FL patients from the Czech Lymphoma Study Group registry treated with frontline rituximab‐containing regimen. Of those, 950 cases received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) and achieved complete or partial remission: 712 patients received rituximab maintenance (MAINT) and 238 were a historical observational cohort (OBS). We have proposed a modified POD24 (mPOD24) endpoint for the chemosensitive patients calculated from the end‐of‐induction (EOI). Survival rates since EOI were as follows: 5‐year overall survival (OS) 86.2% versus 94.5% in the OBS and MAINT groups, respectively (P < .001) and 5‐year progression‐free survival 58.5% (OBS) and 75.4% (MAINT) (P < .001). The Cox proportional hazards model showed a decrease in mPOD24 incidence in the MAINT group with the overall hazard rate reduced by 56% (hazard ratio = 0.44; P < .001). The cumulative incidence of mPOD24 was reduced from 24.1% in OBS to 10.1% in MAINT (P < .001). Comparison of non‐mPOD24 cases showed OS similar to that in the general population. Rituximab maintenance given after R‐CHOP resulted in a 2.4‐fold reduction in mPOD24 incidence. Once the non‐POD24 status is achieved, FL does not shorten the patients’ life expectancy.